Phase 2 Prostate Cancer Trial, Recruiting NCT03424850 Sponsor: Washington University School of Medicine Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT03424850
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with early-stage prostate cancer, confirmed through a tissue or cell sample test.
  • Your cancer is classified as either "low-risk" or "favorable intermediate-risk" based on specific test results, including your PSA level, Gleason score, and biopsy results (confirm with trial site if unsure of your risk category).
  • You may have already started hormone therapy (to lower testosterone), as long as it began no more than 6 months before the planned treatment, and the total course of hormone therapy is between 4 and 36 months.
  • You are at least 18 years old.
  • You are able to carry out daily activities with no more than some limitations due to your health (confirm with trial site what level of physical fitness is required).
  • You are able to understand the study information and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • You have previously had radiation therapy to the prostate or the lower belly/pelvic area.
  • You have had another type of cancer within the last 5 years, unless it was a certain type of skin cancer (basal cell or squamous cell) that was fully removed with minor surgery.
  • You are currently taking part in another clinical trial involving an experimental treatment.
  • You have a serious uncontrolled illness, such as an active infection, heart failure, chest pain, or an irregular heartbeat.
  • You are unable to receive any form of anesthesia (general, spinal, or local).
  • You have had a previous prostate procedure (called a TURP) that left a large enough defect that your doctor believes it would interfere with the planned treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hiram A Gay, M.D., Washington University School of Medicine

Phone: 314-362-8516

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
27 February 2018
Est. completion
28 February 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Biochemical control experienced by patients with prostate cancer treated with an HDR implant

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov